Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CRHR1 | P34998 | 12/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.43 |
| ▸ | VCP | P55072 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1734283 | 0.84 | KDM4E (0.67) | KDM4ECRHR1VCP | |
| SCHEMBL1734511 | 0.83 | KDM4E (0.66) | KDM4ECRHR1ADORA3ADORA1ADORA2A | |
| SCHEMBL1734563 | 0.82 | KDM4E (0.51) | KDM4ECRHR1ADORA3VCP | |
| SCHEMBL1733483 | 0.82 | KDM4E (0.51) | KDM4ECRHR1ADORA3ADORA1VCP | |
| SCHEMBL1734495 | 0.81 | KDM4E (0.51) | KDM4EADORA3ADORA1ADORA2A | |
| SCHEMBL1733468 | 0.81 | KDM4E (0.57) | KDM4ECRHR1ADORA3ADORA1ADORA2A | |
| SCHEMBL1733692 | 0.78 | ADORA3 (0.49) | KDM4EADORA3ADORA1ADORA2A | |
| SCHEMBL1734477 | 0.74 | KDM4E (0.65) | KDM4EADORA3ADORA1ADORA2A | |
| SCHEMBL1734301 | 0.73 | ALDH1A1 (0.42) | KDM4EADORA3ADORA1VCPADORA2A | |
| SCHEMBL1734460 | 0.73 | KDM4E (0.51) | KDM4ECRHR1VCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822451-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-02 | — | — | US | claimed |
| EP-1891018-B1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMA (US) | 2011-11-16 | — | — | EP | claimed |
| WO-2011131686-A1 | A THERMALLY CONTROLLED ASSEMBLY | NAPATECH A/S (DK) | 2011-10-27 | — | — | WO | claimed |
| US-20070105833-A1 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED | 2007-05-10 | — | — | US | claimed |
| US-8822451-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-02 | — | — | US | disclosed |
| US-8822451-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-02 | — | — | US | disclosed |
| US-20070105833-A1 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED | 2007-05-10 | — | — | US | disclosed |
| US-20070105833-A1 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105833-A1 | Modulators of ATP-binding cassette transporters | ABCC4, CFTR, ABCC2 | KDM4E 3910/4885CRHR1 4760/4885ADORA3 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.